KYTX Kyverna Therapeutics
- 4.890
- +0.110+2.30%
Kyverna Therapeutics News
Kyverna Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Aktar Mert
Kyverna Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Aktar Mert
Kyverna Therapeutics | 8-K: Current report
Kyverna Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-JPMORGAN CHASE & CO.(5.5%)
Kyverna Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Biddle Warner Weston
Kyverna Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Shaw Christi
Kyverna Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Biddle Warner Weston
Kyverna Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Shaw Christi
Kyverna Therapeutics | 8-K: Current report
Kyverna Therapeutics | 10-Q: Quarterly report
Kyverna Therapeutics | 8-K: Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Kyverna Therapeutics | 8-K: Current report
Kyverna Therapeutics | UPLOAD: Others
Kyverna Therapeutics | 8-K: Current report
Kyverna Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Walker Karen Marie
Kyverna Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jones Ryan Alexander
Kyverna Therapeutics | 10-Q: Quarterly report
Kyverna Therapeutics | 8-K: Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Kyverna Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Vida Ventures, LLC(11.1%),VV Manager LLC(11.1%), etc.
Kyverna Therapeutics | 10-K: FY2023 Annual Report
Analysis
Price Target
No Data
No Data